Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas

Cancer Science

Volumn 102, Issue 2, 2011, Pages 387-392

  Campos, Benito ^a   Bermejo, Justo Lorenzo ^b,c   Han, Lin ^a,d   Felsberg, Jörg ^e   Ahmadi, Rezvan ^a   Grabe, Niels ^a   Reifenberger, Guido ^e   Unterberg, Andreas ^a   Herold Mende, Christel ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^e HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; NESTIN; NUCLEAR RECEPTOR COREPRESSOR;

ADULT; ARTICLE; ASTROCYTIC GLIOMA; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CORRELATION ANALYSIS; CYTOPLASM; FEMALE; GLIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR RECURRENCE;

ADULT; ASTROCYTOMA; BRAIN NEOPLASMS; CO-REPRESSOR PROTEINS; FEMALE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NUCLEAR RECEPTOR CO-REPRESSOR 1; NUCLEAR RECEPTOR CO-REPRESSOR 2; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79952085666     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01792.x     Document Type: Article

References (21)

1. Lottaz C, Beier D, Meyer K et al. Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Res 2010; 70: 2030-40.
2. Zeppernick F, Ahmadi R, Campos B et al. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 2008; 14: 123-9.
3. Wan F, Herold-Mende C, Campos B et al. Association of stem cell-related genes with patient survival in astrocytic gliomas. Biomarkers (in press).
4. Banwell CM, MacCartney DP, Guy M et al. Altered nuclear receptor corepressor expression attenuates vitamin D receptor signaling in breast cancer cells. Clin Cancer Res 2006; 12: 2004-13.
5. Choi K, Oh S, Kang H et al. The functional relationship between co-repressor N-CoR and SMRT in mediating transcriptional repression by thyroid hormone receptor alpha. Biochem J 2008; 411: 19-26.
6. Khanim FL, Gommersall LM, Wood VHJ et al. Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells. Oncogene 2004; 23: 6712-25.
7. Varlakhanova N, Snyder C, Jose S, Hahm JB, Privalsky ML. Estrogen receptors recruit SMRT and N-CoR corepressors through newly recognized contacts between the corepressor N terminus and the receptor DNA binding domain. Mol Cell Biol 2010; 30: 1434-45.
8. Xu F, Li K, Tian M et al. N-CoR is required for patterning the anterior-posterior axis of zebrafish hindbrain by actively repressing retinoid signaling. Mech Dev 2009; 126: 771-80.
9. Pourcet B, Pineda-Torra I, Derudas B, Staels B, Glineur C. SUMOylation of human peroxisome proliferator-activated receptor alpha inhibits its trans-activity through the recruitment of the nuclear corepressor NCoR. J Biol Chem 2010; 285: 5983-92.
10. Hermanson O, Jepsen K, Rosenfeld MG. N-CoR controls differentiation of neural stem cells into astrocytes. Nature 2002; 419: 934-9.
11. Jepsen K, Solum D, Zhou T et al. SMRT-mediated repression of an H3K27 demethylase in progression from neural stem cell to neuron. Nature 2007; 450: 415-9.
12. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett 2009; 280: 168-76.
13. Cunliffe VT. Eloquent silence: developmental functions of Class I histone deacetylases. Curr Opin Genet Dev 2008; 18: 404-10.
14. Lucio-Eterovic AKB, Cortez MAA, Valera ET et al. Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas. BMC Cancer 2008; 8: 243.
15. Park DM, Li J, Okamoto H et al. N-CoR pathway targeting induces glioblastoma derived cancer stem cell differentiation. Cell Cycle 2007; 6: 467-70.
16. Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 2008; 269: 7-17.
17. Shankar S, Srivastava RK. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. Adv Exp Med Biol 2008; 615: 261-98.
18. Jones P, Steinkühler C. From natural products to small molecule ketone histone deacetylase inhibitors: development of new class specific agents. Curr Pharm Des 2008; 14: 545-61.
19. Khan O, La Thangue NB. Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas. Nat Clin Pract Oncol 2008; 5: 714-26.
20. Battaglia S, Maguire O, Campbell MJ. Transcription factor co-repressors in cancer biology: roles and targeting. Int J Cancer 2010; 126: 2511-9.
21. Galanis E, Jaeckle KA, Maurer MJ et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 2009; 27: 2052-8.